Evidence map›Paper›PMID 25070509›Full record

ArticleGenome biology and evolution2014

Genome evolution and plasticity of Serratia marcescens, an important multidrug-resistant nosocomial pathogen.

Atsushi Iguchi, Yutaka Nagaya, Elizabeth Pradel, Tadasuke Ooka, Yoshitoshi Ogura, Keisuke Katsura, Ken Kurokawa, Kenshiro Oshima, Masahira Hattori, Julian Parkhill and 6 more

Open access · goldAbstract read
In one paragraph

Article in Genome biology and evolution, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 111 papers.

0numbers the graph read from it
0cells of the map it votes in
111citing papers in PubMed
4.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

111 citing papers in PubMed, 189 citations in OpenAlex.

  1. Serratia Bacteraemia in the North Denmark Region: A Population-Based Study (2010-2024).APMIS : acta pathologica, microbiologica, et immunologica Scandinavica · 2026
    Article
  2. Article
  3. Article
  4. From Environmental Organism to Nosocomial Threat:Antibiotics (Basel, Switzerland) · 2026
    Review
  5. Prevalence and activity of class II microcins inApplied and environmental microbiology · 2026
    Article
  6. Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2026
    Review
  7. Article
  8. Article
  9. Genomic Insights Into Multidrug-Resistant FoodborneInternational journal of food science · 2026
    Article
  10. Molecular Epidemiology of Carbapenem-ResistantInfection and drug resistance · 2026
    Article
  11. Article
  12. Article
  13. Genomic and phenotypic insights into Serratia interaction with plants from an ecological perspective.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2025
    Article
  14. Article
  15. Genomes of novelMicrobiology resource announcements · 2025
    Article
  16. Molecular epidemiology of a carbapenem-resistantFrontiers in microbiology · 2025
    Article
  17. Genome-resolved analysis of Serratia marcescens strain SMTT infers niche specialization as a hydrocarbon-degrader.DNA research : an international journal for rapid publication of reports on genes and genomes · 2024
    Article
  18. Article
  19. Article
  20. Article

51 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 9 institutions in 3 countries.

Atsushi IguchiInterdisciplinary Research Organization, University of Miyazaki, JapanPresent address: Department of Animal and Grassland Sciences, Faculty of Agriculture, University of Miyazaki, Japan.
Yutaka NagayaDepartment of Microbiology and Infection Control Science, Kyoto Pharmaceutical University, JapanPresent address: Kashima ONC QC, Oncology DCU, Eisai Demand Chain Systems, Eisai Co., Ltd., Ibaraki, Japan.
Elizabeth PradelCentre d'Immunologie de Marseille-Luminy, UM2 Aix-Marseille Université, Marseille, FranceINSERM, U1104, Marseille, FranceCNRS, UMR7280, Marseille, FrancePresent address: CIIL-Inserm U1019, Institut Pasteur de Lille, Lille, France.
Tadasuke OokaDepartment of Infectious Diseases, Faculty of Medicine, University of Miyazaki, Japan.
Yoshitoshi OguraDepartment of Infectious Diseases, Faculty of Medicine, University of Miyazaki, JapanDepartment of Genomics and Bioenvironmental Science, Frontier Science Research Center, University of Miyazaki, Japan.
Keisuke KatsuraDepartment of Genomics and Bioenvironmental Science, Frontier Science Research Center, University of Miyazaki, Japan.
Ken KurokawaEarth-Life Science Institute, Tokyo Institute of Technology, Kanagawa, Japan.
Kenshiro OshimaGraduate School of Frontier Sciences, University of Tokyo, Chiba, Japan.
Masahira HattoriGraduate School of Frontier Sciences, University of Tokyo, Chiba, Japan.
Julian ParkhillPathogen Genomics, The Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Cambridge, United Kingdom.
Mohamed SebaihiaPathogen Genomics, The Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Cambridge, United Kingdom.
Sarah J CoulthurstDivision of Molecular Microbiology, College of Life Sciences, University of Dundee, United Kingdom.
Naomasa GotohDepartment of Microbiology and Infection Control Science, Kyoto Pharmaceutical University, Japan.
Nicholas R ThomsonPathogen Genomics, The Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Cambridge, United KingdomDepartment of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom nrt@sanger.ac.uk thayash@med.miyazaki-u.ac.jp.
Jonathan J EwbankCentre d'Immunologie de Marseille-Luminy, UM2 Aix-Marseille Université, Marseille, FranceINSERM, U1104, Marseille, FranceCNRS, UMR7280, Marseille, France.
Tetsuya HayashiDepartment of Infectious Diseases, Faculty of Medicine, University of Miyazaki, JapanDepartment of Genomics and Bioenvironmental Science, Frontier Science Research Center, University of Miyazaki, Japan nrt@sanger.ac.uk thayash@med.miyazaki-u.ac.jp.
University of Miyazaki · JPWellcome Sanger Institute · GBThe University of Tokyo · JPCentre d’Immunologie de Marseille-Luminy · FRCentre National de la Recherche Scientifique · FREisai (Japan) · JPKyoto Pharmaceutical University · JPTokyo Institute of Technology · JPUniversity of Dundee · GB

Funding

Wellcome Trust
6 · The paper itself

Abstract

Serratia marcescens is an important nosocomial pathogen that can cause an array of infections, most notably of the urinary tract and bloodstream. Naturally, it is found in many environmental niches, and is capable of infecting plants and animals. The emergence and spread of multidrug-resistant strains producing extended-spectrum or metallo beta-lactamases now pose a threat to public health worldwide. Here we report the complete genome sequences of two carefully selected S. marcescens strains, a multidrug-resistant clinical isolate (strain SM39) and an insect isolate (strain Db11). Our comparative analyses reveal the core genome of S. marcescens and define the potential metabolic capacity, virulence, and multidrug resistance of this species. We show a remarkable intraspecies genetic diversity, both at the sequence level and with regards genome flexibility, which may reflect the diversity of niches inhabited by members of this species. A broader analysis with other Serratia species identifies a set of approximately 3,000 genes that characterize the genus. Within this apparent genetic diversity, we identified many genes implicated in the high virulence potential and antibiotic resistance of SM39, including the metallo beta-lactamase and multiple other drug resistance determinants carried on plasmid pSMC1. We further show that pSMC1 is most closely related to plasmids circulating in Pseudomonas species. Our data will provide a valuable basis for future studies on S. marcescens and new insights into the genetic mechanisms that underlie the emergence of pathogens highly resistant to multiple antimicrobial agents.

Indexed as

Genome, BacterialAnimalsAnti-Bacterial AgentsDrug Resistance, MultipleEvolution, MolecularGenetic VariationHumansInsectaSerratia InfectionsSerratia marcescensAnti-Bacterial Agentsgenome plasticitymultidrug resistanceSerratia marcescensvirulence

Identifiers

PMID25070509
PMCPMC4231636
OpenAlexW2138267773

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.